Update on Extensively Drug-Resistant Salmonella Serotype Typhi Infections Among Travelers to or from Pakistan and Report of Ceftriaxone-Resistant Salmonella Serotype Typhi Infections Among Travelers to Iraq - United States, 2018-2019.

Adolescent Adult Aged Ceftriaxone / pharmacology Child Child, Preschool Disease Outbreaks Drug Resistance, Microbial Female Humans Infant Iraq / epidemiology Male Middle Aged Pakistan / epidemiology Salmonella typhi / drug effects Travel-Related Illness Typhoid Fever / drug therapy United States / epidemiology Young Adult

Journal

MMWR. Morbidity and mortality weekly report

ISSN: 1545-861X

Titre abrégé: MMWR Morb Mortal Wkly Rep

Pays: United States

ID NLM: 7802429

Informations de publication

Date de publication:
22 May 2020

Historique:

entrez: 22 5 2020

pubmed: 22 5 2020

medline: 23 5 2020

Statut: epublish

Résumé

Ceftriaxone-resistant Salmonella enterica serotype Typhi (Typhi), the bacterium that causes typhoid fever, is a growing public health threat. Extensively drug-resistant (XDR) Typhi is resistant to ceftriaxone and other antibiotics used for treatment, including ampicillin, chloramphenicol, ciprofloxacin, and trimethoprim-sulfamethoxazole (1). In March 2018, CDC began enhanced surveillance for ceftriaxone-resistant Typhi in response to an ongoing outbreak of XDR typhoid fever in Pakistan. CDC had previously reported the first five cases of XDR Typhi in the United States among patients who had spent time in Pakistan (2). These illnesses represented the first cases of ceftriaxone-resistant Typhi documented in the United States (3). This report provides an update on U.S. cases of XDR typhoid fever linked to Pakistan and describes a new, unrelated cluster of ceftriaxone-resistant Typhi infections linked to Iraq. Travelers to areas with endemic Typhi should receive typhoid vaccination before traveling and adhere to safe food and water precautions (4). Treatment of patients with typhoid fever should be guided by antimicrobial susceptibility testing whenever possible (5), and clinicians should consider travel history when selecting empiric therapy.

Identifiants

DOI: 10.15585/mmwr.mm6920a2 PMID: 32437343 PMC: PMC7357342

pubmed: 32437343

doi: 10.15585/mmwr.mm6920a2

pmc: PMC7357342

doi:

Substances chimiques

Ceftriaxone 75J73V1629

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

618-622

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Références

Clin Infect Dis. 2017 Nov 29;65(12):e45-e80

pubmed: 29053792

Lancet. 2019 May 18;393(10185):2073-2084

pubmed: 31106753

MMWR Morb Mortal Wkly Rep. 2019 Jan 11;68(1):11-13

pubmed: 30629573

Indian J Med Res. 2019 Mar;149(3):404-411

pubmed: 31249207

Lancet Infect Dis. 2019 May;19(5):467

pubmed: 31034389

Lancet Infect Dis. 2018 Dec;18(12):1368-1376

pubmed: 30507460